Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma-Reference-Cited by-同舟云学术

Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma

Published:2010-07-21 Issue:21 Volume:116 Page:4973-4979
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Brown Jubilee,Smith Judith A.,Ramondetta Lois M.,Sood Anil K.,Ramirez Pedro T.,Coleman Robert L.,Levenback Charles F.,Munsell Mark F.,Jung Maria,Wolf Judith K.

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.25498/fullpdf

Reference38 articles.

1. Cancer statistics, 2009;Jemal;CA Cancer J Clin.,2009

2. Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (phase III): Gynecologic Oncology Group Study No. 122;Randall;J Natl Cancer Inst Monogr.,1995

3. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study;Randall;J Clin Oncol.,2006

4. Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest oncology group study;Poplin;Gynecol Oncol.,1999

5. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study;Miller;Gynecol Oncol.,2002

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T-Box Transcription Factor 2 Enhances Chemoresistance of Endometrial Cancer by Mediating NRF2 Expression;Current Protein & Peptide Science;2022-08

2. Roles of Medicinal Plants and Constituents in Gynecological Cancer Therapy: Current Literature and Future Directions;Current Topics in Medicinal Chemistry;2020-08-17

3. Endometrial carcinoma complicated by malignant pericardial effusion;Medicine;2019-10

4. Does a history of malignancy impact the survival of a subsequent endometrial adenocarcinoma? Should clinical trials eligibility criteria be revisited?;Journal of Obstetrics and Gynaecology;2019-07-29

5. Molecular Markers for Treatment Response and Toxicity of Gemcitabine;Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy;2019